Constipation, polyuria, polydipsia, and edema associated with orlistat

Kathleen A. Packard, Richard L. Wurdeman, Antonio P. Reyes, Wilma M. Guzman-Santos, Chantal Guévremont

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE: To report the occurrence of a novel group of adverse effects associated with initiation and rechallenge of orlistat. CASE SUMMARY: A 42-year-old white woman developed symptoms of constipation, polyuria, polydipsia, and increased lower-leg edema after 2 weeks of treatment with orlistat 120 mg 3 times daily. The drug was discontinued for 4 days and the symptoms resolved. On reinstitution of the orlistat treatment, the symptoms reappeared within 2 days. Thereafter, the medication was permanently discontinued. DISCUSSION: Common gastrointestinal adverse reactions associated with orlistat use include fecal urgency and abdominal pain and discomfort. Pedal edema has also been reported to occur, although less frequently. No reports were discovered documenting the occurrence of constipation, polydipsia, and polyuria associated with the use of orlistat. Despite careful consideration of other possible causes of these symptoms, the temporal association between initiation, discontinuation, and rechallenge of orlistat and the patient's symptoms suggest a medication-related adverse event. Based on the Naranjo probability scale, the likelihood that orlistat was the cause of this cluster of adverse effects is possible. CONCLUSIONS: It is important for the healthcare provider to be aware of these adverse effects to promptly evaluate and differentiate between possible causes of similar reactions.

Original languageEnglish
Pages (from-to)1168-1170
Number of pages3
JournalAnnals of Pharmacotherapy
Volume36
Issue number7-8
StatePublished - 2002

Fingerprint

Polydipsia
Polyuria
Constipation
Edema
orlistat
Health Personnel
Abdominal Pain
Foot
Leg
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Packard, K. A., Wurdeman, R. L., Reyes, A. P., Guzman-Santos, W. M., & Guévremont, C. (2002). Constipation, polyuria, polydipsia, and edema associated with orlistat. Annals of Pharmacotherapy, 36(7-8), 1168-1170.

Constipation, polyuria, polydipsia, and edema associated with orlistat. / Packard, Kathleen A.; Wurdeman, Richard L.; Reyes, Antonio P.; Guzman-Santos, Wilma M.; Guévremont, Chantal.

In: Annals of Pharmacotherapy, Vol. 36, No. 7-8, 2002, p. 1168-1170.

Research output: Contribution to journalArticle

Packard, KA, Wurdeman, RL, Reyes, AP, Guzman-Santos, WM & Guévremont, C 2002, 'Constipation, polyuria, polydipsia, and edema associated with orlistat', Annals of Pharmacotherapy, vol. 36, no. 7-8, pp. 1168-1170.
Packard KA, Wurdeman RL, Reyes AP, Guzman-Santos WM, Guévremont C. Constipation, polyuria, polydipsia, and edema associated with orlistat. Annals of Pharmacotherapy. 2002;36(7-8):1168-1170.
Packard, Kathleen A. ; Wurdeman, Richard L. ; Reyes, Antonio P. ; Guzman-Santos, Wilma M. ; Guévremont, Chantal. / Constipation, polyuria, polydipsia, and edema associated with orlistat. In: Annals of Pharmacotherapy. 2002 ; Vol. 36, No. 7-8. pp. 1168-1170.
@article{e7be5f0e583f4214b39b08be6d820e34,
title = "Constipation, polyuria, polydipsia, and edema associated with orlistat",
abstract = "OBJECTIVE: To report the occurrence of a novel group of adverse effects associated with initiation and rechallenge of orlistat. CASE SUMMARY: A 42-year-old white woman developed symptoms of constipation, polyuria, polydipsia, and increased lower-leg edema after 2 weeks of treatment with orlistat 120 mg 3 times daily. The drug was discontinued for 4 days and the symptoms resolved. On reinstitution of the orlistat treatment, the symptoms reappeared within 2 days. Thereafter, the medication was permanently discontinued. DISCUSSION: Common gastrointestinal adverse reactions associated with orlistat use include fecal urgency and abdominal pain and discomfort. Pedal edema has also been reported to occur, although less frequently. No reports were discovered documenting the occurrence of constipation, polydipsia, and polyuria associated with the use of orlistat. Despite careful consideration of other possible causes of these symptoms, the temporal association between initiation, discontinuation, and rechallenge of orlistat and the patient's symptoms suggest a medication-related adverse event. Based on the Naranjo probability scale, the likelihood that orlistat was the cause of this cluster of adverse effects is possible. CONCLUSIONS: It is important for the healthcare provider to be aware of these adverse effects to promptly evaluate and differentiate between possible causes of similar reactions.",
author = "Packard, {Kathleen A.} and Wurdeman, {Richard L.} and Reyes, {Antonio P.} and Guzman-Santos, {Wilma M.} and Chantal Gu{\'e}vremont",
year = "2002",
language = "English",
volume = "36",
pages = "1168--1170",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "7-8",

}

TY - JOUR

T1 - Constipation, polyuria, polydipsia, and edema associated with orlistat

AU - Packard, Kathleen A.

AU - Wurdeman, Richard L.

AU - Reyes, Antonio P.

AU - Guzman-Santos, Wilma M.

AU - Guévremont, Chantal

PY - 2002

Y1 - 2002

N2 - OBJECTIVE: To report the occurrence of a novel group of adverse effects associated with initiation and rechallenge of orlistat. CASE SUMMARY: A 42-year-old white woman developed symptoms of constipation, polyuria, polydipsia, and increased lower-leg edema after 2 weeks of treatment with orlistat 120 mg 3 times daily. The drug was discontinued for 4 days and the symptoms resolved. On reinstitution of the orlistat treatment, the symptoms reappeared within 2 days. Thereafter, the medication was permanently discontinued. DISCUSSION: Common gastrointestinal adverse reactions associated with orlistat use include fecal urgency and abdominal pain and discomfort. Pedal edema has also been reported to occur, although less frequently. No reports were discovered documenting the occurrence of constipation, polydipsia, and polyuria associated with the use of orlistat. Despite careful consideration of other possible causes of these symptoms, the temporal association between initiation, discontinuation, and rechallenge of orlistat and the patient's symptoms suggest a medication-related adverse event. Based on the Naranjo probability scale, the likelihood that orlistat was the cause of this cluster of adverse effects is possible. CONCLUSIONS: It is important for the healthcare provider to be aware of these adverse effects to promptly evaluate and differentiate between possible causes of similar reactions.

AB - OBJECTIVE: To report the occurrence of a novel group of adverse effects associated with initiation and rechallenge of orlistat. CASE SUMMARY: A 42-year-old white woman developed symptoms of constipation, polyuria, polydipsia, and increased lower-leg edema after 2 weeks of treatment with orlistat 120 mg 3 times daily. The drug was discontinued for 4 days and the symptoms resolved. On reinstitution of the orlistat treatment, the symptoms reappeared within 2 days. Thereafter, the medication was permanently discontinued. DISCUSSION: Common gastrointestinal adverse reactions associated with orlistat use include fecal urgency and abdominal pain and discomfort. Pedal edema has also been reported to occur, although less frequently. No reports were discovered documenting the occurrence of constipation, polydipsia, and polyuria associated with the use of orlistat. Despite careful consideration of other possible causes of these symptoms, the temporal association between initiation, discontinuation, and rechallenge of orlistat and the patient's symptoms suggest a medication-related adverse event. Based on the Naranjo probability scale, the likelihood that orlistat was the cause of this cluster of adverse effects is possible. CONCLUSIONS: It is important for the healthcare provider to be aware of these adverse effects to promptly evaluate and differentiate between possible causes of similar reactions.

UR - http://www.scopus.com/inward/record.url?scp=0036020155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036020155&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 1168

EP - 1170

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 7-8

ER -